Mayersohn Joel David 4
4 · CITIUS ONCOLOGY, INC. · Filed Aug 7, 2025
Insider Transaction Report
Form 4
Mayersohn Joel David
Director
Transactions
- Other
Common Stock
2025-07-28+21,228→ 21,228 total
Holdings
- 250,000
Stock Option (Right to Buy)
Exercise: $1.07Exp: 2034-12-12→ Common Stock (250,000 underlying)
Footnotes (2)
- [F1]The shares were acquired through a distribution in kind to limited partners of 10XYZ Holdings, which was the Sponsor of TenX Keane Acquisition ("TenX"), the legacy entity of Citius Oncology, Inc.
- [F2]The options were granted on December 12, 2024. The options will vest 100% on the one-year anniversary of the grant date, provided that the Optionee provides Continuous Service to the Company as of the vesting date.